Cellectis S.A. (EPA: ALCLS)
Market Cap | 210.20M |
Revenue | 18.33M |
Net Income | -73.64M |
Shares Out | 100.09M |
EPS | -1.04 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 21,963 |
Open | 2.135 |
Previous Close | 2.070 |
Day's Range | 2.040 - 2.135 |
52-Week Range | 0.888 - 3.440 |
Beta | 3.22 |
Analysts | n/a |
Price Target | n/a |
Earnings Date | Sep 6, 2024 |
About Cellectis
Cellectis S.A., a clinical stage biotechnological company, develops products based on gene-editing with a portfolio of allogeneic chimeric antigen receptor T-cells product candidates. The company is developing ALLO-715 and ALLO-605 for the treatment of multiple myeloma; ALLO-501 to treat large B-cell lymphoma; ALLO-316, an allogeneic engineered CAR T-cell product targeting CD70; ALLO-819 to treat acute myeloid leukemia; ALLO-213 for the treatment of small cell lung cancer; and ALLO-182 to treat gastric and pancreatic cancer. It also develops UC... [Read more]
News
![](https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1044548366/image_1044548366.jpg?io=getty-c-w1536)
Cellectis: Cheap With Promising But Speculative Cancer Therapies
Cellectis S.A. offers innovative CAR-T therapies for cancer with promising pipeline candidates like UCART22 for ALL and CLLS52. Click for more on CLLS stock.
![](https://cdn.snapi.dev/images/v1/m/t/press16-2609677.jpg)
Cellectis Publishes a Molecular Therapy Article on a SMART DUAL CAR T-cell Approach for Treating Recalcitrant Solid Tumors
NEW YORK, Aug. 26, 2024 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to deve...
Cellectis Non-GAAP EPS of -$0.22 beats by $0.09, revenue of $9.5M misses by $0.2M
![](https://cdn.snapi.dev/images/v1/m/w/press9-2572625.jpg)
Cellectis Appoints Dr. Adrian Kilcoyne as Chief Medical Officer
NEW YORK, Aug. 07, 2024 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to deve...
![](https://cdn.snapi.dev/images/v1/t/i/press7-2571744.jpg)
Cellectis Provides Financial Results for the Second Quarter 2024
NEW YORK, Aug. 06, 2024 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene editing platform to deve...
![](https://cdn.snapi.dev/images/v1/w/b/press8-2562546.jpg)
FDA Grants Orphan Drug Designation to Cellectis' CLLS52 (alemtuzumab) For ALL Treatment
NEW YORK, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to dev...
![](https://cdn.snapi.dev/images/v1/g/l/press1-2546697.jpg)
FDA Grants Orphan Drug and Rare Pediatric Disease Designation Status to Cellectis' UCART22 product candidate for Acute Lymphoblastic Leukemia (ALL) Treatment
NEW YORK, July 25, 2024 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to dev...
![](https://cdn.snapi.dev/images/v1/j/5/press5-2502811.jpg)
Cellectis Reports Results from Shareholders Meeting Held on June 28, 2024
NEW YORK, June 28, 2024 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS; Nasdaq: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving c...
![](https://cdn.snapi.dev/images/v1/x/9/press11-2489119.jpg)
Cellectis Publishes a Scientific Article Unveiling Three Key Factors for Efficient TALE Base Editing
NEW YORK, June 20, 2024 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to dev...
![](https://cdn.snapi.dev/images/v1/f/h/press14-2476657.jpg)
Cellectis Unveils a Non-Viral Gene Therapy Approach for Sickle Cell Disease in Nature Communications
NEW YORK, June 12, 2024 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to de...
![](https://cdn.snapi.dev/images/v1/r/x/press17-2462534.jpg)
Cellectis Receives Orphan Drug Designation for UCART22, its Allogeneic CAR T Product for Patients with Acute Lymphoblastic Leukemia
NEW YORK, June 04, 2024 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to dev...
![](https://cdn.snapi.dev/images/v1/g/p/press6-2452625.jpg)
Cellectis' Annual Shareholders General Meeting to be Held on June 28, 2024
NEW YORK, May 29, 2024 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS- NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develo...
![](https://cdn.snapi.dev/images/v1/j/b/press5-2450618.jpg)
Cellectis Reports Financial Results for First Quarter 2024
• Cellectis announced completion of the additional equity investment of $140M by AstraZeneca • Cash position of $143 million as of March 31, 2024 1 ; cash runway projection into 2026 2 • Conference...
![](https://cdn.snapi.dev/images/v1/2/a/conf12-2449090.jpg)
Cellectis to Report First Quarter 2024 Financial Results on May 28, 2024
NEW YORK, May 27, 2024 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS- NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develo...
![](https://cdn.snapi.dev/images/v1/j/a/press17-2411224.jpg)
Cellectis Announces Completion of the Additional Equity Investment by AstraZeneca
Completion of the additional equity investment of $140M by AstraZeneca, as previously announced on November 1 and 15, 2023 NEW YORK, May 06, 2024 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS ...
![](https://cdn.snapi.dev/images/v1/k/z/press2-2407751.jpg)
Cellectis Appoints Arthur Stril as Interim Chief Financial Officer
NEW YORK, May 02, 2024 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS – NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to devel...
![](https://cdn.snapi.dev/images/v1/r/o/press1-2398385.jpg)
Cellectis Reports Financial Results for the Fourth Quarter and Full Year 2023
• Preliminary results of NATHALI-01 and updated results of BALLI-01 Phase I clinical studies presented at the American Society of Hematology (ASH) 65th Annual Meeting
![](https://cdn.snapi.dev/images/v1/j/p/press8-2384202.jpg)
Cellectis Presents Novel TALEN® Editing Processes Enabling Highly Efficient Gene Correction and Gene Insertion in HSPCs
This novel editing approach might unlock new strategies for the treatment of metabolic and neurological diseases Non-viral circular ssDNA delivery associated to TALEN® gene editing allows high levels ...
![](https://cdn.snapi.dev/images/v1/c/v/press8-2366252.jpg)
Cellectis Publishes a Novel Intronic Gene Editing Approach For the Treatment of Inborn Metabolic Diseases by Edited HSPCs
Cellectis publishes an approach that could unlock new therapeutic avenues for the treatment of inborn metabolic diseases as well as neurological diseases
![](https://cdn.snapi.dev/images/v1/o/m/press10-2361923.jpg)
Cellectis Announces Two Poster Presentations on Novel TALEN® Editing Process for Gene Correction and Gene Insertion in HSPCs at the ASGCT Annual Meeting
NEW YORK, April 08, 2024 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to dev...
![](https://cdn.snapi.dev/images/v1/y/2/press19-2231532.jpg)
Cellectis announces the drawdown of the second tranche of €15 million under the credit facility agreement entered with the European Investment Bank (EIB)
NEW YORK, Jan. 16, 2024 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS – NASDAQ: CLLS) (the “Company”), a clinical-stage biotechnology company using its pioneering gene-editing platform to deve...
![](https://cdn.snapi.dev/images/v1/a/n/press8-2206987.jpg)
Cellectis Reports Results from Shareholders Meeting Held on December 22, 2023
NEW YORK, Dec. 22, 2023 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS; Nasdaq: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving c...
![](https://cdn.snapi.dev/images/v1/l/h/press1-2163997.jpg)
Cellectis' Shareholders Meeting to be Held on December 22, 2023
NEW YORK, Nov. 17, 2023 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS; Nasdaq: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving ...
![](https://cdn.snapi.dev/images/v1/h/t/press13-2158628.jpg)
Cellectis Announces the execution of the Subsequent Investment Agreement with AstraZeneca
NEW YORK, Nov. 15, 2023 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS – NASDAQ: CLLS) today anounced that, following the consultation of its works council, it has now signed a binding Subsequ...
![](https://cdn.snapi.dev/images/v1/k/o/press16-2142668.jpg)
Cellectis Reports Financial Results for Third Quarter and First Nine Months 2023
• Strategic Collaboration and Investment Agreements signed with AstraZeneca Updated results of the Phase I BALLI-01 Trial evaluating UCART22 in r/r B-cell ALL and preliminary results of the Phase I N...